

*AMENDMENTS TO THE CLAIMS*

This listing of claims will replace all prior versions, and listings, of claims in the application.

*Listing of Claims*

Claim 1 (Currently amended): An isolated peptide selected from the group consisting of:

Conotoxin-Af6: X<sub>6</sub>GQDDSX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>DSQX<sub>2</sub>VMX<sub>2</sub>HGQRRERR<sup>^</sup> (SEQ ID NO:1);

Conotoxin-Bt1: GGX<sub>1</sub>X<sub>1</sub>VRX<sub>1</sub>SAX<sub>1</sub>TLHX<sub>1</sub>LTX<sub>5</sub><sup>^</sup> (SEQ ID NO:2);

Conotoxin-Bt2: GGX<sub>1</sub>X<sub>1</sub>VRX<sub>1</sub>SAX<sub>1</sub>TLHX<sub>1</sub>ITX<sub>5</sub><sup>^</sup> (SEQ ID NO:3);

Conotoxin-Bt3: DGX<sub>1</sub>X<sub>1</sub>VRX<sub>1</sub>AAX<sub>1</sub>TLNX<sub>1</sub>LTX<sub>5</sub><sup>^</sup> (SEQ ID NO:4);

Conotoxin-Bt4: GYX<sub>1</sub>DDRX<sub>1</sub>IAX<sub>1</sub>TVRX<sub>1</sub>LX<sub>1</sub>X<sub>1</sub>A# (SEQ ID NO:5);

Conotoxin-Bt5: GGGX<sub>1</sub>VRX<sub>1</sub>SAX<sub>1</sub>TLHX<sub>1</sub>ITX<sub>5</sub><sup>^</sup> (SEQ ID NO:6);

Conotoxin-Bu1: NX<sub>5</sub>X<sub>1</sub>TX<sub>3</sub>IX<sub>1</sub>IVX<sub>1</sub>ISRX<sub>1</sub>LX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:7);

Conotoxin-Bu2: NX<sub>5</sub>X<sub>1</sub>TX<sub>3</sub>X<sub>3</sub>NLX<sub>1</sub>LVX<sub>1</sub>ISRX<sub>1</sub>LX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:8);

Conotoxin-C1: SDX<sub>1</sub>X<sub>1</sub>LLRX<sub>1</sub>DVX<sub>1</sub>TVLX<sub>1</sub>LX<sub>1</sub>RN# (SEQ ID NO:9);

Conotoxin-C2: GDX<sub>1</sub>X<sub>1</sub>LLRX<sub>1</sub>DVX<sub>1</sub>TVLX<sub>1</sub>LX<sub>1</sub>RD# (SEQ ID NO:10);

Conotoxin-C3: SDX<sub>1</sub>X<sub>1</sub>LLRX<sub>1</sub>DVX<sub>1</sub>TVLX<sub>1</sub>PX<sub>1</sub>RN# (SEQ ID NO:11);

Conotoxin-C4: IX<sub>1</sub>X<sub>1</sub>GLIX<sub>1</sub>DLX<sub>1</sub>TARX<sub>1</sub>RDS# (SEQ ID NO:12);

Conotoxin-C5: IX<sub>1</sub>X<sub>1</sub>GLIX<sub>1</sub>DLX<sub>1</sub>AARX<sub>1</sub>RDS# (SEQ ID NO:13);

Conotoxin-C6: GX<sub>1</sub>X<sub>5</sub>X<sub>1</sub>VGSIX<sub>5</sub>X<sub>1</sub>AVRQQX<sub>1</sub>CIRNNNNRX<sub>5</sub>X<sub>4</sub>CX<sub>5</sub>X<sub>2</sub><sup>^</sup> (SEQ ID NO:14);

Conotoxin-Di1: TITAX<sub>1</sub>X<sub>1</sub>AX<sub>1</sub>RTSX<sub>1</sub>RMSSM# (SEQ ID NO:15);

Conotoxin-Di2: X<sub>6</sub>X<sub>1</sub>TX<sub>5</sub>X<sub>5</sub>X<sub>1</sub>X<sub>1</sub>VX<sub>1</sub>RHTX<sub>1</sub>RLKSM# (SEQ ID NO:16);

Conotoxin-Ep1: GGKDIVX<sub>1</sub>TITX<sub>1</sub>LX<sub>1</sub>X<sub>2</sub>I# (SEQ ID NO:17);

Application Serial No. 10/092,367  
Amendment Dated 7 April 2004  
Reply to Office Action of 7 October 2003

Conotoxin-Fi1: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>VAX<sub>1</sub>MAAX<sub>1</sub>IARX<sub>1</sub>NQAN# (SEQ ID NO:18);  
Conotoxin-Fi2: SX<sub>3</sub>X<sub>1</sub>QARX<sub>1</sub>VQX<sub>1</sub>AVNX<sub>1</sub>LX<sub>2</sub>X<sub>1</sub>R# (SEQ ID NO:19);  
Conotoxin-Fi2a: SX<sub>3</sub>X<sub>1</sub>QARX<sub>1</sub>VQX<sub>1</sub>AVNX<sub>1</sub>LX<sub>2</sub>X<sub>1</sub>RGX<sub>2</sub>X<sub>2</sub>IIMLGVX<sub>5</sub>R-  
DTRQF<sup>^</sup> (SEQ ID NO:20);  
Conotoxin-Fi3: D X<sub>3</sub>X<sub>1</sub>DDRX<sub>1</sub>IAX<sub>1</sub>TVRX<sub>1</sub>LX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:21);  
Conotoxin-Fi4: GNTAX<sub>1</sub>X<sub>1</sub>VRX<sub>1</sub>AAX<sub>1</sub>TLHX<sub>1</sub>LSL<sup>^</sup> (SEQ ID NO:22);  
Conotoxin-Fi5: GSISM GFX<sub>1</sub>HRRX<sub>1</sub>IAX<sub>1</sub>LVRX<sub>1</sub>LAX<sub>1</sub>I# (SEQ ID NO:23);  
Conotoxin-L1: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>VAX<sub>1</sub>MAAX<sub>1</sub>IARX<sub>1</sub>NAAN# (SEQ ID NO:24);  
Conotoxin-L2: GX<sub>2</sub>X<sub>1</sub>X<sub>1</sub>DRX<sub>1</sub>IVX<sub>1</sub>TVRX<sub>1</sub>LX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:25);  
Conotoxin-L3: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>VAX<sub>2</sub>MAAX<sub>1</sub>LTRX<sub>1</sub>X<sub>1</sub>AVX<sub>2</sub># (SEQ ID NO:26);  
Conotoxin-P1: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>HSX<sub>2</sub>X<sub>3</sub>QX<sub>1</sub>CLRX<sub>1</sub>VRVNX<sub>2</sub>VQQX<sub>1</sub>C<sup>^</sup> (SEQ ID  
NO:27);  
Conotoxin-P2: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>HSX<sub>2</sub>X<sub>3</sub>QX<sub>1</sub>CLRX<sub>1</sub>VRVNNVQQX<sub>1</sub>C<sup>^</sup> (SEQ ID  
NO:28);  
Conotoxin-P3: GX<sub>1</sub>X<sub>1</sub>X<sub>1</sub>HSX<sub>2</sub>X<sub>3</sub>QX<sub>1</sub>CLRX<sub>1</sub>IRVNX<sub>2</sub>VQQX<sub>1</sub>C<sup>^</sup> (SEQ ID  
NO:29);  
Conotoxin-P4: GX<sub>1</sub>AX<sub>1</sub>HX<sub>3</sub>AFQX<sub>1</sub>CLRX<sub>1</sub>INVNX<sub>2</sub>VQQX<sub>1</sub>C<sup>^</sup> (SEQ ID  
NO:30);  
Conotoxin-P5: GLX<sub>1</sub>X<sub>1</sub>DIX<sub>1</sub>FIX<sub>1</sub>TIX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:31);  
Conotoxin-Sm1: ITX<sub>1</sub>TDIX<sub>1</sub>LVMX<sub>2</sub>LX<sub>1</sub>X<sub>1</sub>I# (SEQ ID NO:32);  
wherein X<sub>1</sub> is Glu or  $\gamma$ -carboxyglutamic acid (Gla); X<sub>2</sub> is Lys, nor-Lys, N-methyl-Lys,  
N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; X<sub>3</sub> is Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr,  
O-phospho-Tyr or nitro-Tyr; X<sub>4</sub> is Trp (D or L) or halo-Trp (D or L); X<sub>5</sub> is Pro or hydroxy-Pro; and  
X<sub>6</sub> is Gln or pyroglutamate.

Application Serial No. 10/092,367  
Amendment Dated 7 April 2004  
Reply to Office Action of 7 October 2003

Claim 2 (original): A derivative of the peptide of claim 1, in which the Arg residues may be substituted by Lys, ornithine, homoarginine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, nor-Lys, or any synthetic basic amino acid; the Tyr residues may be substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any synthetic hydroxy containing amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the Phe residues may be substituted with any synthetic aromatic amino acid; the Trp residues may be substituted with Trp (D), neo-Trp, halo-Trp (D or L) or any aromatic synthetic amino acid; the Asn, Ser, Thr or Hyp residues may be glycosylated; the Tyr residues may also be substituted with the 3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho-Tyr, respectively) and corresponding O-sulpho- and O-phospho-derivatives; the acidic amino acid residues may be substituted with any synthetic acidic amino acid; and the aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains  $C_nH_{2n+2}$  up to and including n=8.

Claims 3-4 (canceled).

Claim 5 (Currently amended): An isolated conopeptide propeptide having an amino acid sequence ~~set forth in Table 4 selected from the group consisting of the amino acid sequences set forth in SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:61, SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, and SEQ ID NO:130.~~

Application Serial No. 10/092,367  
Amendment Dated 7 April 2004  
Reply to Office Action of 7 October 2003

Claims 6-24 (canceled).

Claim 25 (new): The isolated peptide of claim 1, wherein the peptide is conotoxin-Bt5.

Claim 26 (new): A derivative of the peptide of claim 25, in which the Arg residues may be substituted by Lys, ornithine, homoarginine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, nor-Lys, or any synthetic basic amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the acidic amino acid residues may be substituted with any synthetic acidic amino acid; and the aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains  $C_nH_{2n+2}$  up to and including  $n=8$ .

Claim 27 (new): The isolated peptide of claim 25, wherein the peptide has the sequence GGGX<sub>1</sub>VRX<sub>2</sub>SAX<sub>3</sub>TLHX<sub>4</sub>ITP<sup>5</sup> (SEQ ID NO:138).

Claim 28 (new): A derivative of the peptide of claim 27, in which the Arg residues may be substituted by Lys, ornithine, homoarginine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, nor-Lys, or any synthetic basic amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the acidic amino acid residues may be substituted with any synthetic acidic amino acid; and the aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains  $C_nH_{2n+2}$  up to and including  $n=8$ .

Application Serial No. 10/092,367  
Amendment Dated 7 April 2004  
Reply to Office Action of 7 October 2003

Claim 29 (new): The isolated conopeptide propeptide of claim 5, wherein the peptide has the amino acid sequence set forth in SEQ ID NO:73.